COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,241 Articles (22,733 medRxiv, 8,508 bioRxiv)

Most recent first Previous |  Page 2621: Articles 26201-26210  | Next

COVID-19: Dying is Bad--Losing Life is Worse
Wetzler, H. P., Wetzler, E. A., Cobb, H. W.
10.1101/2020.06.08.20050559 — Posted: 2020-06-12 Discussion: Onsite
Pre exposure Hydroxychloroquine use is associated with reduced COVID19 risk in healthcare workers
Bhattacharya, R., Chowdhury, S., Mukherjee, R., Nandi, A., Kulshrestha, M., Ghosh, R., Saha, S.
10.1101/2020.06.09.20116806 — Posted: 2020-06-12
A short therapeutic regimen based on hydroxychloroquine plus azithromycin for the treatment of COVID-19 in patients with non-severe disease. A strategy associated with a reduction in hospital admissions and complications.
Oteo, J. A., Marco, P., Ponce de Leon, L., Roncero, A., Lobera, T., Lisa, V.
10.1101/2020.06.10.20101105 — Posted: 2020-06-12
Hydroxychloroquine Proves Ineffective in Hamsters and Macaques Infected with SARS-CoV-2
Rosenke, K., Jarvis, M., Feldmann, F., Schwarz, B., Okumura, A., Lovaglio, J., Saturday, G., Hanley, P., Meade-White, K., Williamson, B., Hansen, F., Perez-Perez, L., Leventhal, S., Tang-Huau, T.-L., Nason, M., Callison, J., Haddock, E., Scott, D., Sewell, G., Bosio, C., Hawman, D., de Wit, E., Feldmann, H.
10.1101/2020.06.10.145144 — Posted: 2020-06-11 Discussion: Onsite | Offsite
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schafer, A., Ziwawo, C. T., DiPiazza, A. T., Dinnon, K. H., Elbashir, S. M., Shaw, C. A., Woods, A., Fritch, E. J., Martinez, D. R., Bock, K. W., Minai, M., Nagata, B. M., Hutchinson, G. B., Bahl, K., Garcia-Dominguez, D., Ma, L., Renzi, I., Kong, W.-P., Schmidt, S. D., Wang, L., Zhang, Y., Stevens, L. J., Phung, E., Chang, L. A., Loomis, R. J., Altaras, N. E., Narayanan, E., Metkar, M., Presnyak, V., Liu, C., Louder, M. K., Shi, W., Leung, K., Yang, E. S., West, A., Gully, K. L., Wang, N., Wrapp, D., Doria-Rose, N. A., Stewart-Jones, G., Bennett, H., Nason, M. C., Ruckwardt, T. J., McLellan, J. S., Denison, M. R., Chappell, J. D., Moore, I. N., Morabito, K. M., Mascola, J. R., Baric, R. S., Carfi, A., Graham, B. S.
10.1101/2020.06.11.145920 — Posted: 2020-06-11 Discussion: Onsite | Offsite
COVID-19 Variants Database: A repository for Human SARS-CoV-2 Polymorphism Data
Rakha, A., Rasheed, H., Batool, Z., Akram, J., Adnan, A., Du, J.
10.1101/2020.06.10.145292 — Posted: 2020-06-11 Discussion: Onsite
Investigation of the effect of temperature on the structure of SARS-Cov-2 Spike Protein by Molecular Dynamics Simulations
Rath, S. L., Kumar, K.
10.1101/2020.06.10.145086 — Posted: 2020-06-11
Hijacking SARS-Cov-2/ACE2 receptor interaction by natural and semi-synthetic steroidal agents acting on functional pockets on receptor binding region
Carino, A., Moraca, F., Fiorillo, B., Marcano, S., Sepe, V., Biagioli, M., Finamore, C., Bozza, S., Francisci, D., Distrutti, E., Catalanotti, B., Zampella, A., Fiorucci, S.
10.1101/2020.06.10.144964 — Posted: 2020-06-11
Chimeric synthetic reference standards enable cross-validation of positive and negative controls in SARS-CoV-2 molecular tests.
Madala, B. S., Reis, A. L. M., Deveson, I. W., Rawlinson, W., Mercer, T. R.
10.1101/2020.06.09.143412 — Posted: 2020-06-11
Shielding and Beyond: The Roles of Glycans in SARS-CoV-2 Spike Protein
Casalino, L., Gaieb, Z., Dommer, A. C., Harbison, A. M., Fogarty, C. A., Barros, E. P., Taylor, B. C., Fadda, E., Amaro, R. E.
10.1101/2020.06.11.146522 — Posted: 2020-06-11

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).